导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.62% | 2971/4773 |
| 近一周 | -2.69% | 2852/5462 |
| 近一月 | -3.89% | 2056/5421 |
| 近一季 | -11.76% | 3767/5209 |
| 近半年 | -9.43% | 3493/4920 |
| 近一年 | -0.24% | 2697/4366 |
| 近两年 | 62.34% | 1143/2954 |
| 近三年 | 16.83% | 1590/2253 |
| 成立以来 | 67.52% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.59% 1870/4961 |
14.67% 1774/5312 |
- - |
- - |
| 2025 | 26.54% 1623/4813 |
4.13% 990/3635 |
2.68% 1426/4076 |
17.95% 2388/4524 |
0.34% 2051/4813 |
| 2024 | -2.25% 2190/3463 |
-11.01% 2401/2808 |
-8.41% 2233/3014 |
15.53% 1690/3129 |
3.80% 764/3463 |
| 2023 | -5.73% 767/2656 |
8.81% 443/2280 |
-3.38% 783/2385 |
-7.56% 1591/2515 |
-3.00% 573/2655 |
| 2022 | -21.20% 1015/2207 |
-14.84% 1006/1919 |
3.64% 1119/2016 |
-11.58% 547/2113 |
0.97% 1413/2208 |
| 2021 | 20.26% 184/1822 |
-5.09% 906/1255 |
12.40% 336/1330 |
4.36% 359/1466 |
8.03% 168/1822 |
| 2020 | 19.97% 726/1250 |
-1.79% 239/1028 |
16.77% 413/1067 |
4.61% 948/1164 |
- 1065/1184 |
| 2019 | 24.48% 616/1092 |
29.50% 271/739 |
-8.28% 590/788 |
-0.80% 619/850 |
5.65% 694/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 广发中证1000ETF联接C VS. 长安沪深300非周期A(740101) |